Karyopharm Therapeutics Inc. - Common Stock (KPTI)

Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

KPTI earnings call for the period ending December 31, 2024.

KPTI earnings call for the period ending September 30, 2024.

KPTI earnings call for the period ending June 30, 2024.

KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.

KPTI earnings call for the period ending March 31, 2024.

KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

KPTI earnings call for the period ending December 31, 2023.

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

KPTI earnings call for the period ending September 30, 2023.

  On Wednesday, 59 companies achieved new lows for the year.

KPTI earnings call for the period ending June 30, 2023.